Lipid formulations for delivery of therapeutic agents
AssigneeArbutus Biopharma Corporation
InventorsEd Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
Life of this patent
Estimating the term…
Loading patent…
AssigneeArbutus Biopharma Corporation
InventorsEd Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
Estimating the term…
The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.
A nucleic acid-lipid particle consisting essentially of:
Dependencies are inferred from the claim text.